

Reduce the Risk of OHE Recurrence in Adults—With XIFAXAN

XIFAXAN earned AASLD/EASL's highest possible recommendation (GRADE I, A, 1) as an add-on therapy to lactulose to reduce the risk of OHE recurrence after a recurrence while on lactulose alone.*

In a clinical study, adults with a history of OHE took one XIFAXAN 550 mg tablet twice daily for 6 months (n=140) or placebo (n=159). 91% of patients took lactulose at the same time. The results were:



XIFAXAN group: 22% reported breakthrough HE episode.

PLACEBO group: 46% reported breakthrough HE episode.



XIFAXAN group: 14% of the patients had a hospitalization involving HE.

PLACEBO group: 23% patients had a hospitalization involving HE.

XIFAXAN has excellent insurance coverage, as low as \$0 copay for eligible[†] commercially insured patients

[†]Patient is not eligible if he/she participates in, seeks reimbursement or submits a claim for reimbursement to any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state healthcare program (each a Government Program), or where prohibited by law. Patient must be enrolled in, and must seek reimbursement from or submit a claim for reimbursement to, a commercial insurance plan. Offer excludes full-cash-paying patients. Maximum benefits and other restrictions apply. Visit <https://xifaxan.copaysavingsprogram.com> or call 1-866-XIFAXAN for full eligibility criteria, terms, and conditions.

OHE = overt hepatic encephalopathy, AASLD = American Association for the Study of Liver Diseases, EASL = European Association for the Study of the Liver.

*Per the GRADE System for Evidence: Grade I=randomized, controlled trials; A=evidence is "high quality," and further research is very unlikely to change our confidence in the estimated effect; and 1=recommendation is "strong," with factors influencing strength of recommendation, including the quality of evidence, presumed patient-important outcomes, and costs.

INDICATION

XIFAXAN[®] (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults.

IMPORTANT SAFETY INFORMATION

- XIFAXAN is not for everyone. Do not take XIFAXAN if you have a known hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN.
- If you take antibiotics, like XIFAXAN, there is a chance you could experience diarrhea caused by an overgrowth of bacteria (*C. difficile*). This can cause symptoms ranging in severity from mild diarrhea to life-threatening colitis. Contact your healthcare provider if your diarrhea does not improve or worsens.
- Talk to your healthcare provider before taking XIFAXAN if you have severe hepatic (liver) impairment, as this may cause increased effects of the medicine.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.

Talk to your doctor to see if XIFAXAN is right for you.



98% of commercially insured patients have coverage for XIFAXAN

Plus, XIFAXAN is covered for 100% of Medicare patients, and those eligible for both Medicare and Medicaid may receive XIFAXAN for \$10.35/month.*

*Visit www.healthcare.gov to see if you qualify for Medicaid.



Save on prescriptions

Eligible[†] commercially insured patients may pay as little as \$0 for XIFAXAN

[†]Patient is not eligible if he/she participates in, seeks reimbursement or submits a claim for reimbursement to any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state healthcare program (each a Government Program), or where prohibited by law. Patient must be enrolled in, and must seek reimbursement from or submit a claim for reimbursement to, a commercial insurance plan. Offer excludes full-cash-paying patients. Maximum benefits and other restrictions apply. Visit <https://xifaxan.copaysavingsprogram.com> or call 1-866-XIFAXAN for full eligibility criteria, terms, and conditions.

How to take XIFAXAN



Take one 550 mg tablet of **XIFAXAN** twice daily by mouth



Take **XIFAXAN** with or without food



Take **XIFAXAN** as long as your health care provider recommends

IMPORTANT SAFETY INFORMATION (continued)

- Tell your healthcare provider if you are taking drugs called P-glycoprotein and/or OATPs inhibitors (such as cyclosporine) because using these drugs with XIFAXAN may lead to an increase in the amount of XIFAXAN absorbed by your body.
- In a clinical study, the most common side effects of XIFAXAN in HE (≥10%) were peripheral edema (swelling, usually in the ankles or lower limbs), nausea (feeling sick to your stomach), dizziness, fatigue (feeling tired), and ascites (a buildup of fluid in the abdomen).
- XIFAXAN may affect warfarin activity when taken together. Tell your healthcare provider if you are taking warfarin because the dose of warfarin may need to be adjusted to maintain proper blood-thinning effect.
- If you are pregnant, planning to become pregnant, or nursing, talk to your healthcare provider before taking XIFAXAN because XIFAXAN may cause harm to an unborn baby or nursing infant.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch/ or call **1-800-FDA-1088**.

For product information, adverse event reports, and product complaint reports, please contact:
Salix Product Information Call Center
Phone: 1-800-321-4576
Fax: 1-510-595-8183
Email: salixmc@dlss.com

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.